EU's CHMP recommends Merck & Co's Sycrest for bipolar but not schizophrenia
This article was originally published in Scrip
The EU's CHMP has endorsed the approval of Merck & Co's Sycrest (asenapine) 5mg and 10mg sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults, but has rejected an indication for schizophrenia.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.